Recombinant severe respiratory syndrome coronavirus 2 Rbd trimer protein vaccine capable of generating broad-spectrum cross neutralization activity, and preparation method and use thereof
US12324833B2 · kind B2 · utility
0Cited by
2References
20Claims
0Family size
Inventors
Key dates
| Filing date | Sep 24, 2021 |
| Grant date | Jun 10, 2025 |
| Priority date | — |
| Expiry date | Sep 24, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a recombinant RBD trimer protein capable of simultaneously generating cross neutralization activity for various severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) epidemic strains. The RBD trimer protein is taken as an antigen and supplemented with an adjuvant to immunize an organism, so that a high-titer neutralizing antibody aiming at various SARS-COV-2 epidemic strains can be generated at the same time, and the antibody has a certain broad-spectrum property and can be used for treating and/or preventing SARS-COV-2 infection and/or coronavirus disease 2019.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.